Chengdu Kanghong Pharmaceutical Group Co., Ltd. (pharmaceuticals and health products) Adhering to the mission of 'researching, manufacturing, selling and disseminating professional and innovative pharmaceutical products and knowledge, fundamentally improving patients' individual physical fitness and the effectiveness of social medical care, and promoting the progress of human health — keeping the world healthy and benefiting all beings', Chengdu Kanghong Pharmaceutical Group Co., Ltd. has established the business philosophy of 'innovating products and services to benefit people's livelihood and the public'. 'Conbercept Ophthalmic Injection' is a landmark product of Chinese pharmaceutical innovation and China's first original Class I biological new drug to obtain a WHO International Nonproprietary Name (INN). The product was first launched in China in March 2014, filling the market gap in domestically produced drugs for the treatment of macular degeneration and breaking the monopoly of high-priced imported drugs on the Chinese ophthalmic market. In March 2016, Conbercept Ophthalmic Injection was named 'the most clinically valuable innovative drug'; in December 2017, Conbercept's substance patent won the China Patent Gold Award; and on 9 December 2018, the project 'Development of the national Class I new drug Conbercept Ophthalmic Injection' won the highest award in China's industrial field, the fifth 'China Industrial Award'. Kanghong Pharmaceutical firmly practises the cultural concept of 'gratitude in the heart, repayment in action', bravely assumes corporate social responsibility and continuously increases its social contribution. The Group has long made constant efforts in rural revitalization, patient assistance, education donations, earthquake relief, poverty alleviation and the dissemination of public welfare culture; by the end of 2025, its cumulative donations of money and goods had exceeded RMB 673 million. In 2019, the Group was named by the All-China Federation of Industry and Commerce and the State Council Poverty Alleviation Office as an advanced private enterprise in the national 'Ten Thousand Enterprises Helping Ten Thousand Villages' targeted poverty alleviation campaign. In addition, the Group has established a series of branded charity programmes centred on the 'Langshijie · Muguangming' public welfare fund. In 2023, the Group won the '12th China Charity Award'. 17 qualification certificates are published on the official website; Official website: https://www.cnkh.com/.Chengdu Kanghong Jituan Pharmaceutical is an enterprise located in Sichuan Province, mainly engaged in pharmaceutical.Its main products and services include Lifeisitediyanye, Bolisuannadiyanye, Pulaluofendiyanye, Shuganjieyu Capsule, Youzuopikelongpian, Yansuanwenlafaxinhuanshipian.For more details, please visit the official website https://www.cnkh.com/. Official website: https://www.cnkh.com/.
Chengdu Kanghong Pharmaceutical Group Co., Ltd. (pharmaceuticals and health products) Adhering to the mission of 'researching, manufacturing, selling and disseminating professional and innovative pharmaceutical products and knowledge, fundamentally improving patients' individual physical fitness and the effectiveness of social medical care, and promoting the progress of human health — keeping the world healthy and benefiting all beings', Chengdu Kanghong Pharmaceutical Group Co., Ltd. has established the business philosophy of 'innovating products and services to benefit people's livelihood and the public'. 'Conbercept Ophthalmic Injection' is a landmark product of Chinese pharmaceutical innovation and China's first original Class I biological new drug to obtain a WHO International Nonproprietary Name (INN). The product was first launched in China in March 2014, filling the market gap in domestically produced drugs for the treatment of macular degeneration and breaking the monopoly of high-priced imported drugs on the Chinese ophthalmic market. In March 2016, Conbercept Ophthalmic Injection was named 'the most clinically valuable innovative drug'; in December 2017, Conbercept's substance patent won the China Patent Gold Award; and on 9 December 2018, the project 'Development of the national Class I new drug Conbercept Ophthalmic Injection' won the highest award in China's industrial field, the fifth 'China Industrial Award'. Kanghong Pharmaceutical firmly practises the cultural concept of 'gratitude in the heart, repayment in action', bravely assumes corporate social responsibility and continuously increases its social contribution. The Group has long made constant efforts in rural revitalization, patient assistance, education donations, earthquake relief, poverty alleviation and the dissemination of public welfare culture; by the end of 2025, its cumulative donations of money and goods had exceeded RMB 673 million. In 2019, the Group was named by the All-China Federation of Industry and Commerce and the State Council Poverty Alleviation Office as an advanced private enterprise in the national 'Ten Thousand Enterprises Helping Ten Thousand Villages' targeted poverty alleviation campaign. In addition, the Group has established a series of branded charity programmes centred on the 'Langshijie · Muguangming' public welfare fund. In 2023, the Group won the '12th China Charity Award'. 17 qualification certificates are published on the official website; Official website: https://www.cnkh.com/.Chengdu Kanghong Jituan Pharmaceutical is an enterprise located in Sichuan Province, mainly engaged in pharmaceutical.Its main products and services include ophthalmic solutions such as sodium hyaluronate eye drops, anti inflammatory eye drops, capsules for depression and cardiovascular care.For more details, please refer to the link below. Official website: https://www.cnkh.com/.
